230 related articles for article (PubMed ID: 27811856)
1. Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours.
Laskaratos FM; Walker M; Naik K; Maragkoudakis E; Oikonomopoulos N; Grant L; Meyer T; Caplin M; Toumpanakis C
Br J Cancer; 2016 Nov; 115(11):1321-1327. PubMed ID: 27811856
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life.
Faggiano A; Carratù AC; Guadagno E; Tafuto S; Tatangelo F; Riccardi F; Mocerino C; Palmieri G; Damiano V; Siciliano R; Leo S; Mauro A; Tozzi LF; Battista C; De Rosa G; Colao A
Oncotarget; 2016 Feb; 7(5):5538-47. PubMed ID: 26701729
[TBL] [Abstract][Full Text] [Related]
3. Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.
Allaw MB; Switchenko JM; Khalil L; Wu C; Alese OB; Akce M; Draper A; Jones AT; El-Rayes B; Shaib W
Oncology; 2022; 100(3):131-139. PubMed ID: 35078191
[TBL] [Abstract][Full Text] [Related]
4. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Rinke A; Müller HH; Schade-Brittinger C; Klose KJ; Barth P; Wied M; Mayer C; Aminossadati B; Pape UF; Bläker M; Harder J; Arnold C; Gress T; Arnold R;
J Clin Oncol; 2009 Oct; 27(28):4656-63. PubMed ID: 19704057
[TBL] [Abstract][Full Text] [Related]
5. Impact of octreotide long-acting release on tumour growth control as a first-line treatment in neuroendocrine tumours of pancreatic origin.
Jann H; Denecke T; Koch M; Pape UF; Wiedenmann B; Pavel M
Neuroendocrinology; 2013; 98(2):137-43. PubMed ID: 23797176
[TBL] [Abstract][Full Text] [Related]
6. Objective radiological disease control with sandostatin monotherapy in metastatic neuroendocrine tumours.
Khasraw M; Townsend A; Price T; Hart J; Bell D; Pavlakis N
Intern Med J; 2010 Jun; 40(6):453-8. PubMed ID: 20636828
[TBL] [Abstract][Full Text] [Related]
7. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival.
Rinke A; Wittenberg M; Schade-Brittinger C; Aminossadati B; Ronicke E; Gress TM; Müller HH; Arnold R;
Neuroendocrinology; 2017; 104(1):26-32. PubMed ID: 26731483
[TBL] [Abstract][Full Text] [Related]
8. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
Pavel ME; Hainsworth JD; Baudin E; Peeters M; Hörsch D; Winkler RE; Klimovsky J; Lebwohl D; Jehl V; Wolin EM; Öberg K; Van Cutsem E; Yao JC;
Lancet; 2011 Dec; 378(9808):2005-2012. PubMed ID: 22119496
[TBL] [Abstract][Full Text] [Related]
9. INITIATION OF PATIENTS ONTO LONG-ACTING SOMATOSTATIN ANALOGUE THERAPY FOR NEUROENDOCRINE TUMORS: A SINGLE-CENTER REVIEW OF PRACTICE.
Tadman M; Charlton P; Jafar-Mohammadi B; Talbot D; Grossman AB
Endocr Pract; 2018 Feb; 24(2):189-194. PubMed ID: 29466059
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
11. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.
Cives M; Kunz PL; Morse B; Coppola D; Schell MJ; Campos T; Nguyen PT; Nandoskar P; Khandelwal V; Strosberg JR
Endocr Relat Cancer; 2015 Feb; 22(1):1-9. PubMed ID: 25376618
[TBL] [Abstract][Full Text] [Related]
12. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
Diamantopoulos LN; Laskaratos FM; Kalligeros M; Shah R; Navalkissoor S; Gnanasegaran G; Banks J; Smith J; Jacobs B; Galanopoulos M; Mandair D; Caplin M; Toumpanakis C
Neuroendocrinology; 2021; 111(7):650-659. PubMed ID: 32541155
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME
Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569
[TBL] [Abstract][Full Text] [Related]
14. Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors.
Shen C; Xu Y; Dasari A; Shih YC; Yao JC
Oncologist; 2016 Mar; 21(3):308-13. PubMed ID: 26911407
[TBL] [Abstract][Full Text] [Related]
15. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
Toumpanakis C; Garland J; Marelli L; Srirajaskanthan R; Soh J; Davies P; Buscombe J; Caplin ME
Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
[TBL] [Abstract][Full Text] [Related]
17. Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors.
Lau SC; Abdel-Rahman O; Cheung WY
Med Oncol; 2018 Aug; 35(9):123. PubMed ID: 30078166
[TBL] [Abstract][Full Text] [Related]
18. Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge.
Pusceddu S; Prinzi N; Raimondi A; Corti F; Buzzoni R; Di Bartolomeo M; Seregni E; Maccauro M; Coppa J; Milione M; Mazzaferro V; de Braud F
Tumori; 2019 Apr; 105(2):113-120. PubMed ID: 29714658
[TBL] [Abstract][Full Text] [Related]
19. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors.
Strosberg J; Kvols L
World J Gastroenterol; 2010 Jun; 16(24):2963-70. PubMed ID: 20572298
[TBL] [Abstract][Full Text] [Related]
20. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
Cives M; Strosberg J
Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
